KYNTRA BIO, INC.
About KYNTRA BIO, INC.
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $6.4M
- Net income
- $183.5M
- Total assets
- $119.6M
- Market cap
- $27.2M
Source: SEC EDGAR · updated Jun 7, 2026
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $27.2M
- Shares outstanding
- 4.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 14, 2014
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $183.5M in FY2025.
- Trading 30% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review KYNTRA BIO, INC..
Write a review
News about KYNTRA BIO, INC.
News & sentiment via Polygon.io
